• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs

by August 13, 2025
written by August 13, 2025

More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone, saying it poses ‘serious risks to women.’

In a letter obtained by Fox News Digital, 22 attorneys general called on Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drugs Administration head Martin Makary to bring back safeguards for the pills that were scrapped by the Obama and Biden administrations.

‘Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug’s label, while the drug is less than half as effective as claimed. These facts directly contradict the drug’s primary marketing message of ‘safe’ and ‘effective,” the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPA), a Washington, D.C.-based advocacy group.

The EPPA report claims the pill presents harm to women, causing 1 in 10 patients to experience a ‘serious adverse event,’ including hemorrhage, emergency room visits and ectopic pregnancy.

The letter, led by Kansas Attorney General Kris Kobach, comes after Kennedy Jr. asked Makary to review the latest data on mifepristone and its safety.

‘Based on that review, the FDA should consider reinstating safety protocols that it identified as necessary as recently as 2011 in its issuance of a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, but which were removed by the Obama and Biden administrations,’ the letter reads, adding that the drug should be taken off the market if safeguards cannot be put in place.

‘Alternatively, in light of the serious risks to women who are presently being prescribed this drug without crucial safeguards, and in the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria,’ the attorneys general wrote.

Sen. Josh Hawley, R-Mo., also sent a letter to Kennedy Jr. last month urging him to take immediate action to reinstate safety guardrails on mifepristone following the secretary’s commitment to conducting a safety review of the drug.

Makary had previously said that he had no plans to modify policies surrounding mifepristone but that the FDA would act if the data suggested there was a safety issue.

Mifepristone, which is taken with another drug called misoprostol to end an early pregnancy, was first approved by the FDA in 2000 after ‘a thorough and comprehensive review’ found it was safe and effective, according to the agency’s website, which noted that periodic reviews since its approval have not identified new safety concerns.

Last year, the Supreme Court rejected a challenge targeting the drug’s availability. The plaintiffs had sought to restrict access to mifepristone across the country, including in Democrat-led states where abortion remains legal. The court did not rule on whether the FDA acted lawfully when it moved during the Obama and Biden administrations to ease the rules for mifepristone’s use that had been established during the Clinton administration.

Medication abortions made up more than half of all abortions in the U.S. health care system in 2023, according to a study by the Guttmacher Institute.

‘Currently, a woman can obtain a mifepristone abortion by participating in only one telehealth visit with any approved healthcare provider (not necessarily a physician), ordering the drugs through a mail-order pharmacy, and self-administering them,’ the attorneys general wrote. ‘And the prescriber is only required to report an adverse event if he or she becomes aware that the patient has died.’

‘The FDA’s removal of these crucial safety protocols in 2016 (and in 2023) that only five years before the FDA considered necessary begs the question of whether the removal was motivated by considerations other than the safety of patients … The current FDA’s dedication to the health and wellbeing of all Americans is encouraging, as is the much-needed review of mifepristone that Secretary Kennedy has promised,’ the letter concludes.

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
Ashley Biden files for divorce from husband, Howard Krein, after 13 years of marriage: reports
next post
Musk threatens ‘immediate’ legal action against Apple over alleged antitrust violations

related articles

Inside Trump’s ultimatum that forced Netanyahu to the...

October 23, 2025

Vance rebukes Israel on ‘very stupid’ vote to...

October 23, 2025

Top Republican slams Katherine Clark for admitting suffering...

October 23, 2025

Vance calls Psaki comments about wife Usha ‘disgraceful’

October 23, 2025

Trump yet to endorse in VA governor’s race...

October 23, 2025

DAVID MARCUS: Trump’s ballroom is no vanity project,...

October 23, 2025

Examining the next threat from Communist China: Our...

October 23, 2025

Sparks fly as Cuomo, Mamdani tear into each...

October 23, 2025

Trump meets NATO’s Rutte amid canceled Putin meeting:...

October 22, 2025

Schumer blocks 12th GOP bid to reopen government...

October 22, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • JD Vance, Treasury Sec Scott Bessent to meet with Zelenskyy as Trump team sets sights on Russia-Ukraine war

    February 11, 2025
  • RUBY CHEN: Trump NSA pick Mike Waltz can help US crush Hamas

    November 21, 2024
  • Panama Canal CEO denies Trump claim that China in control, says end of Carter neutrality treaty means ‘chaos’

    January 9, 2025
  • Trump-backed bill to rein in federal judges gets House-wide vote

    April 8, 2025
  • UN urges diplomacy as Iran hits nuclear ‘gas pedal,’ conservative commentator tells Trump ‘do not appease’

    January 22, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (6,503)
  • Investing (634)
  • Stock (941)

Latest Posts

  • Not ‘honest’ news organizations: White House defends yanking $9B ‘worth of crap’ in rescissions package

    July 17, 2025
  • Oil executives bluntly criticize Trump tariffs and ‘drill, baby, drill’ mantra

    March 27, 2025
  • China’s AI innovation is ‘accelerating’ but US remains dominant, White House says

    April 9, 2025

Recent Posts

  • Extreme heat makes flying harder. Airlines and airports say they aren’t sweating it.

    July 29, 2024
  • Biden-Harris admin accused of ‘too little, too late’ to save the people of war-torn, famine-stricken Sudan

    October 14, 2024
  • Trump previously predicted Biden would pardon son Hunter

    December 2, 2024

Editor’s Pick

  • Senators leapfrog House Republicans on anticipated Trump budget bill

    February 5, 2025
  • Harris claims Trump abortion platform makes ‘no exception,’ moments after Trump says the opposite

    September 11, 2024
  • Obama officials, Trump critics target Hegseth’s Ukraine ‘concessions’ as ‘biggest gift’ to Russia

    February 13, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock